CAS: 857876-30-3; N-(3,3-Dimethylindolin-6-yl)-2-((Pyridin-4-Ylmethyl)Amino)Nicotinamide Diphosphate
该化合物是一种小分子抑制剂,针对血管内皮生长因子受体(VeGFRs),小板本生长因子受体(PDGFRs)和干细胞因子受体(c-Kit),它通过有选择地堵塞对肿瘤生长和转移至关重要的抗逆转素性动脉酶信号路径,表现出强大的抗血管和抗肿瘤活动;二磷酸盐形式提高了溶性和生物利用率,促进了配方的开发;临床和临床研究表明,它有效抑制了肿瘤的生长,特别是在甲状癌和非小细胞肺癌中,其特征精密的药用基因特征和定向机制使它成为进行肿瘤研究和治疗应用的宝贵候选者.
- 英文名称N-(3,3-Dimethylindolin-6-yl)-2-((Pyridin-4-Ylmethyl)Amino)Nicotinamide Diphosphate
- 中文名称二磷酸莫替沙尼
- IUPAC名称N-(3,3-dimethylindolin-6-yl)-2-((pyridin-4-ylmethyl)amino)nicotinamide bis(phosphate)
- 其它别名Motesanib (Diphosphate); Motesanib Phosphate [jan]; N-(3,3-Dimethyl-1,2-Dihydroindol-6-yl)-2-(Pyridin-4-Ylmethylamino)Pyridine-3-Carboxamide Diphosphate; Trans-3-(5-Methyl-2-Furyl)Acrolein; Motesanib Diphosphate; N-(3,3-Dimethy
- CAS编号857876-30-3
- MFCD编号:MFCD12407403
- FDA UNII编号:T6Q3060U91
- 分子式:C22H29N5O9P2分子量:569.45
- 产品CID: 1856750
- 同类组份化合物CAS453562-69-1 (free base)857876-30-3 (phosphate)
- 产品分类生物化工 → 抑制剂 → 蛋白酪氨酸激酶
- 相似结构搜索
- InChIKey: ONDPWWDPQDCQNJ-UHFFFAOYSA-N
- ONDPWWDPQDCQNJ-UHFFFAOYSA-N
- 计算化学: 氢键受体数9.0氢键供体数6.0可旋转键数5.0
物理性质
- 沸点858.7 °C at 760 mmHg
- 闪点473.1 °C
- PSA:257.57
- LogP:2.7819
- 蒸汽压2.04E-31 mmHg at 25 °C
- 溶解性≥28.45 mg/mL In DMSO; Insoluble In H2O; ≥3.47 mg/mL In Etoh With Ultrasonic
- 外观形态白色至类白色粉末
- 储存条件惰性气氛,存放于冰箱中, -20°C
- 产品应用该化合物是VEGFR1/2/3(IC50=2 NM/3 NM/6 NM,分别为2 NM/3)的具有竞争力的抑制剂,对KIT(C-KIT)有类似的抑制性活动,对VEGBFR的展览超过10倍,对PDGFFR和RET的展览则有10倍的选择性.它显示了针对人类五氯乙酸乙酸酯家族的广泛活动,在EGEFR,SRC和P38 KINASES上有1倍的选择. 磷酸二甲酯大大抑制了VEFGF引起的HVIC(IC50 = 10 NM)扩散,但不会抑制FGUF引起的扩散(IC 50 > 3 000 NM).它还有效抑制了PDFFFM引起的扩散 (IC50代表207 NM)和SC引起的CFC引起的C-KIT磷酸化(IC =37 NM);同时,它没有显示对EGGFEFFE磷酸或A431细胞活性的影响.尽管在HUVEVS中没有防止这些细胞辐射,但是这些细胞扩散.
合成工艺路线路线简述
海关参考信息
- 2902600000-乙苯
2902700000-异丙基苯
2912110000-甲醛
2933310010-吡啶 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-12435055-B2
优先权日:2019-08-06
标 题 :3-methylideneoxan-4-one compounds and substituted derivates thereof as inhibitors of telomerase
发明人：SCHEIDT KARL A; BETORI RICK C
权利人:UNIV NORTHWESTERN
摘要:Disclosed are 3-methylideneoxan-4-one compounds, derivatives thereof, and methods of their synthesis and methods of their use in treating a disease or disorder in a subject in need thereof, such as diseases and disorders that are associated with telomerase activity such as cancer. The disclosed compounds may be formulated in a pharmaceutical composition for treating diseases and disorders that are associated with telomerase activity such as cancer.
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Çelenk M, Yıldırım H, Tektemur A, Balbaba M, Erdağ M. Effect of topical motesanib in experimental corneal neovascularization model. Int Ophthalmol. 2023 Aug;43(8):2989-2997. doi: 10.1007/s10792-023-02685-3. Epub 2023 Mar 27. 41(4):2482-2490. doi: 10.3892/or.2019.7005. Epub 2019 Feb 11.
166:244-251. doi: 10.1016/j.jpba.2019.01.023. Epub 2019 Jan 14. 48(2):433-449. doi: 10.1159/000491775. Epub 2018 Jul 17. 23(9):1006-e104. doi: 10.1634/theoncologist.2018-0294. Epub 2018 May 31.
6: Gosselin NH, Mouksassi MS, Lu JF, Hsu CP. Population pharmacokinetic modeling of motesanib and its active metabolite, M4, in cancer patients. Clin Pharmacol Drug Dev. 2015 Nov;4(6):463-72. doi: 10.1002/cpdd.196. Epub 2015 Jul 23. 15(12):1771-80. doi: 10.1517/14656566.2014.938639. 31(2):107-46. 37(7):1378-94. doi: 10.1124/dmd.108.025742. Epub 2009 Apr 16. 359(25):2727; author reply 2727. doi: 10.1056/NEJMc081635. 30(8):643-72. 48(4):619-21. doi: 10.1080/02841860802495362. Motesanib Thyroid Cancer Study Group. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008 Jul 3;359(1):31-42. doi: 10.1056/NEJMoa075853. 26(5):455-62. doi: 10.1007/s10637-008-9144-1. Epub 2008 Jun 24.
合成参考文献
参考文献:10.1007/s12094-006-0175-9
摘要:Soto JL, Barbera VM, Saceda M, Carrato A. Molecular biology of exocrine pancreatic cancer. Clinical and Translational Oncology. 2006 May;8(5):306–12. doi: 10.1007/s12094-006-0175-9.
参考文献:10.1007/s10637-014-0113-6
摘要:Kim CA, Price-Hiller J, Chu QS, Tankel K, Hennig R, Sawyer MB, Spratlin JL. Atypical reversible posterior leukoencephalopathy syndrome (RPLS) induced by cediranib in a patient with metastatic rectal cancer. Invest New Drugs. 2014 Oct;32(5):1036–45. doi: 10.1007/s10637-014-0113-6.
参考文献:10.1007/s00261-017-1050-6
摘要:Alessandrino F, Krajewski KM, Tirumani SH, Braschi-Amirfarzan M, Jagannathan JP, Ramaiya NH, Di Salvo DN. Biliary and pancreatic complications of molecular targeted therapies in cancer imaging. Abdom Radiol (NY). 2017 Jun;42(6):1721–33. doi: 10.1007/s00261-017-1050-6.
参考文献:10.1007/bf03256278
摘要:Rutkowski P, Debiec-Rychter M, Ruka W. Gastrointestinal stromal tumors: key to diagnosis and choice of therapy. Mol Diagn Ther. 2008;12(3):131–43. doi: 10.1007/bf03256278.
📝 需求与反馈
尽可能描述清楚需求与问题信息
